ESMO: European Society for Medical Oncology

1. Clinical Benefit of Pembrolizumab in Previously Treated Advanced MSI-H/dMMR Non-colorectal Cancers

   The results of KEYNOTE-158 study

2. Divergent HLA Allele Linked to Immunotherapy Efficacy

   Researchers uncover how immune checkpoint inhibitor response relies on the evolved efficiency of HLA-mediated immunity

3. FDA Approves Luspatercept-aamt for Anaemia in Patients with Beta Thalassemia

   Evidence for efficacy is based on the results from the BELIEVE trial

4. Cancer-Related Cognitive Impairment in Cancer Survivors

   Detection and management strategies

5. Crizotinib in c-MET- or ROS1-positive Non-Small Cell Lung Cancer

   The results of the AcSé phase II study